18 February 2022

Safety update of pharmaceutical product Mavenclad (cladribine)

Reference: CIR-2022-00000037

To all Health facilities / all health care practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the circular issued by the MOHAP for perusal and adhere to what is stated

 

Safety update of pharmaceutical product Mavenclad (cladribine)

 

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

اضافة تحذير على المنتج الطبي Mavenclad-1.pdf:

View Document